TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22088245
Drug: Felodipine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine (5 mg/d) plus Metoprolol (47.5 mg/d)
Study: 7636648
Drug: DTaP vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTaP vaccine (booster dose)
Study: 2794204
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate at 40 meq/L
Study: 2794204
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate at 100 meq/L
Study: 2794204
Drug: 0 meq/L
Normalized name: Sodium Chloride 0.9% with Potassium Chloride 20 mEq/L
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 meq/L sodium bicarbonate
Study: 2794204
Drug: 10 meq/L
Normalized name: Dextrose 5% and Water with Potassium Chloride 10 mEq/L
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 meq/L sodium bicarbonate
Study: 21334626
Drug: Lifestyle intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lifestyle intervention (nutrition education, exercise therapy, psychological care)
Study: 15145924
Drug: Sildenafil (Sil)
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sildenafil (Sil) 3 x 40 mg/day
Study: 8062500
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate (30 mg every 6 hours) with hydrochlorothiazide/amiloride (50 mg/5 mg daily)
Study: 8062500
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate (30 mg every 6 hours) with placebo
Study: 30562225
Drug: Local infiltration
Normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local infiltration anaesthesia (LIA) with 150 ml of ropivacaine 0.2% at the end of surgery.
Study: 30562225
Drug: Single-shot sciatic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-shot sciatic nerve block with 20 ml of ropivacaine 0.75% and adductor canal block with catheter infusion of ropivacaine 0.2% at 6 ml/h for less than 4 days.
Study: 27988180
Drug: Insulin lispro
Normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin lispro mix 25
Study: 21415269
Drug: High-dose daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose daunorubicin and autologous HCT in favorable-risk AML
Study: 21415269
Drug: High-dose daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose daunorubicin and autologous HCT in intermediate-risk AML
Study: 17299489
Drug: 0-60 g
Normalized name: dimethicone
DrugBank: Dimethicone (DB11074)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0-60 g of retrograded resistant maltodextrins (RRM)
Study: 17299489
Drug: Gradually increasing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gradually increasing doses of RRM over 21 days
Study: 17299489
Drug: >60 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: >60 g RRM
Study: 14734593
Drug: Ranolazine (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranolazine (750 mg or 1000 mg, twice daily)
Study: 28286115
Drug: Augmented renal
Normalized name: Sus scrofa renal pelvis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Augmented renal clearance (ARC) patients receiving β-lactam therapy
Study: 28286115
Drug: Patients without
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients without augmented renal clearance (no ARC) receiving β-lactam therapy
Study: 28286115
Drug: Both ARC
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both ARC and no ARC patients receiving β-lactam therapy
Study: 23295775
Drug: Collaborative group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collaborative group intervention (10 weekly group sessions and 2 booster meetings)
Study: 21867621
Drug: High-dose methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose methotrexate (HD-MTX) - CF + VDT protocol
Study: 12173945
Drug: 6 g;pdd(‐1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 g;pdd(‐1) of CLA with 3 g;pdd(‐1) of fatty acids for 28 days
Study: 12173945
Drug: 9 g;pdd(‐1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9 g;pdd(‐1) of an olive oil placebo for 28 days
Study: 2200896
Drug: Midazolam 0.2
Normalized name: midazolam 0.2 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.2 mg.kg‐1
Study: 8597965
Drug: Midazolam 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.4 mg.kg‐1
Study: 8597965
Drug: Midazolam 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.6 mg.kg‐1
Study: 4820642
Drug: Heparin and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin and fresh frozen plasma
Study: 22985565
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid (5 mg once a year)
Study: 22985565
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Vitamin D3 and Caltrate daily for a year)
Study: 18570599
Drug: Fexofenadine 180
Normalized name: fexofenadine 180 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fexofenadine 180 mg once each morning
Study: 18570599
Drug: Chlorpheniramine 6
Normalized name: carbetapentane-chlorpheniramine 60 mg-5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpheniramine 6 mg (2 mg in the morning and 4 mg after 12 h)
Study: 15912655
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C supplementation (1,000 mg/day)
Study: 12478147
Drug: Re-dosing based
Normalized name: Re-Covr
Approvals — FDA: no, EMA: no, PMDA: no
Description: Re-dosing based on serum testosterone
Study: 10718909
Drug: Insulin (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin (0.15 U/kg)
Study: 10718909
Drug: Naloxone and
Normalized name: Naloxone and oxycodone only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone and vasopressin in combination
Study: 8794436
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg micronized 17 beta‐estradiol continuously
Study: 8794436
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg micronized 17 beta‐estradiol continuously
Study: 8794436
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg and 2 mg 17 beta‐estradiol alternating every 42 days
Study: 1352247
Drug: Azelastine 2
Normalized name: azelastine 2.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azelastine 2 mg b.d. p.o. for 10 days
Study: 6466017
Drug: Sodium restriction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium restriction (40 mEq of sodium daily)
Study: 30623236
Drug: IA-HA (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: IA-HA (2 ml/week, for 3 weeks)
Study: 30623236
Drug: IA-CS (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: IA-CS (1 ml)
Study: 30623236
Drug: IA-PRP (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: IA-PRP (4 ml, 3 times, every 3 weeks)
Study: 29224460
Drug: Rocking chair
Normalized name: TRIGLYCERIDES,MEDIUM CHAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocking chair therapy (vestibular stimulation)
Study: 27132044
Drug: Citalopram (30mg,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (30mg, oral)
Study: 17614188
Drug: Tooth mousse
Normalized name: Sus scrofa tooth preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tooth mousse (CPP-ACP agent) applied on group A
Study: 17614188
Drug: Tooth mousse
Normalized name: Sus scrofa tooth preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tooth mousse (CPP-ACP agent) applied on group C
Study: 17614188
Drug: No agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: No agent applied on group B
Study: 17614188
Drug: No agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: No agent applied on group D
Study: 16261661
Drug: Parenteral polyestradiol
Normalized name: POLYESTRADIOL
DrugBank: Polyestradiol phosphate (DB09369)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Parenteral polyestradiol phosphate (PEP) therapy (240 mg/month)
Study: 12016597
Drug: Preoperative administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative administration of morphine, ketamine, and clonidine (150 microg x kg(‐1) of morphine, 150 microg x kg(‐1) of ketamine, and 5 microg x kg(‐1) of clonidine)
Study: 12016597
Drug: Postoperative administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative administration of morphine, ketamine, and clonidine (150 microg x kg(‐1) of morphine, 150 microg x kg(‐1) of ketamine, and 5 microg x kg(‐1) of clonidine)
Study: 30092782
Drug: Potassium excretion
Normalized name: Potassium
DrugBank: Potassium (DB14500)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potassium excretion
Study: 8821992
Drug: 1600 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1600 micrograms of inhaled beclomethasone dipropionate (BDP) daily for at least 3 months
Study: 8821992
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg of oral prednisolone for 3 weeks
Study: 6289058
Drug: Cimetidine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (200 mg three times a day and 400 mg at night)
Study: 26437056
Drug: Low-dose cyclophosphamide
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose cyclophosphamide 2 g/m2 + G-CSF (arm A)
Study: 27485453
Drug: G-CSF alone
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF alone (arm B)
Study: 21464679
Drug: 2-week supply
Normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 2-week supply of nicotine patches
Study: 21464679
Drug: 4-week supply
Normalized name: milnacipran
DrugBank: Milnacipran (DB04896)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4-week supply of nicotine patches
Study: 21464679
Drug: 6-week supply
Normalized name: perampanel
DrugBank: Perampanel (DB08883)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 6-week supply of nicotine patches
Study: 10848721
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 3.3% doxepin and 0.025% capsaicin
Study: 9085951
Drug: Femoral nerve
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Femoral nerve block (FNB) with 30 mL of 3% alkalinized chloroprocaine
Study: 9085951
Drug: Spinal anesthesia
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal anesthesia with 65 mg of 5% hyperbaric lidocaine
Study: 8285849
Drug: Cyproterone acetate;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyproterone acetate; specific dosage and duration not mentioned
Study: 3781705
Drug: Diltiazem (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (60 mg three times daily for three weeks)
Study: 24809884
Drug: Body Cream
Normalized name: Udderly Smooth Body Cream
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Body Cream (Eucerin Eczema Relief Body Crème) applied twice daily for 14 days, followed by a 5-day regression period.
Study: 24809884
Drug: Instant Therapy
Normalized name: Monistat Simple Therapy
DrugBank: Synthetic camphor (DB14156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Instant Therapy (Eucerin Eczema Relief Instant Therapy) for active atopic dermatitis lesions administered for 14 days.
Study: 7958119
Drug: Combination dose
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination dose aerosol of fenoterol hydrobromide (200 micrograms) and ipratropium bromide (80 micrograms)
Study: 3314464
Drug: Metoprolol 100
Normalized name: metoprolol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol 100 mg administered twice daily
Study: 26573073
Drug: Prophylactic minocycline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic minocycline (100 mg twice per day for 4 weeks)
Study: 26573073
Drug: Reactive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reactive treatment (after rash developed, per grade of rash)
Study: 26573073
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment unless severe (grade 3)
Study: 24496086
Drug: Stellate ganglion
Normalized name: Mastocarpus stellatus extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stellate ganglion block (SGB) with 5 mL of 0.5% bupivacaine
Study: 24496086
Drug: Sham injection
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham injection of saline
Study: 22562434
Drug: Total parenteral
Normalized name: TPN - total parenteral nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total parenteral nutrition (TPN) with long-chain triglycerides (LCTs)
Study: 12235653
Drug: Soy (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy (100 g/day)
Study: 12235653
Drug: Tea extract
Normalized name: Tea Extract
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tea extract (3 g/day)
Study: 12235653
Drug: Vegetables (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vegetables (400 g/day as 134 g broccoli, 134 g brussels sprouts, and 134 g petits pois)
Study: 12235653
Drug: High red
Normalized name: acid red 35
Approvals — FDA: no, EMA: no, PMDA: no
Description: High red meat diet (420 g/day)
Study: 10460065
Drug: Grapefruit juice
Normalized name: grapefruit juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grapefruit juice (200 mL, double-strength, three times a day for 2 days) with atorvastatin (40 mg)
Study: 10460065
Drug: Grapefruit juice
Normalized name: grapefruit juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grapefruit juice (200 mL, double-strength, three times a day for 2 days) with pravastatin (40 mg)
Study: 7543131
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of diet and exercise advice (DE, n = 39)
Study: 2523528
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg triamcinolone diacetate (TR)
Study: 2523528
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg of preservative-free morphine (MP)
Study: 2523528
Drug: Both triamcinolone
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Both triamcinolone and morphine (TR and MP)
Study: 974610
Drug: Oxprenolol (beta-blocking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxprenolol (beta-blocking agent)
Study: 25751506
Drug: Seasonal WIV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seasonal WIV vaccine (sWIV) - one dose
Study: 25751506
Drug: Pandemic WIV
Normalized name: pangamate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pandemic WIV vaccine (pWIV) - two doses
Study: 25751506
Drug: Commercially available
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Commercially available trivalent comparator vaccine - one dose followed by placebo
Study: 19203569
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg test formulation of risperidone
Study: 19203569
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg test formulation of risperidone
Study: 19203569
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg reference formulation of risperidone
Study: 19203569
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg reference formulation of risperidone
Study: 17540193
Drug: Nesiritide (28-day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nesiritide (28-day continuous infusion)
Study: 17540193
Drug: Placebo (28-day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (28-day continuous infusion)
Study: 15213581
Drug: Methylphenidate plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate plus psychosocial treatment (parent training, counseling, social skills training, psychotherapy, academic assistance)
Study: 15213581
Drug: Methylphenidate plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate plus attention psychosocial control treatment
Study: 11181810
Drug: Moxonidine (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxonidine (0.2 mg twice a day)
Study: 8220653
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg fluoxetine (FXT)
Study: 8220653
Drug: Carbohydrate (CHO)
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate (CHO) breakfast (80 g maltodextrin, 300 kcal)
Study: 3114812
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of physostigmine for 2 h
Study: 30071838
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of at least three different classes of psychiatric drugs
Study: 30071838
Drug: FGA alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: FGA alone therapy
Study: 30071838
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of drugs from two different classes
Study: 16847198
Drug: Psoralen-UV-A (PUVA)
Normalized name: Psoralen
DrugBank: Psoralen (DB18665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psoralen-UV-A (PUVA) therapy
Study: 16847198
Drug: Narrowband UV-B
Normalized name: Influenza B virus B/Brisbane/60/2008 antigen (UV, formaldehyde inactivated)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Narrowband UV-B (NB-UVB) therapy
Study: 8636825
Drug: Baseline cortisol
Normalized name: cortisol succinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline cortisol concentrations < 414 nmol/L (15.0 micrograms/dl)
Study: 1473127
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (15 ml/d, equivalent to 3.1 g of n-3 fatty acid per day)
Study: 1473127
Drug: Placebo (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (15 ml/d saline)
Study: 28931520
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg HIV-MAG DNA vaccine coadministered with pIL-12 at 0, 250, 1,000, or 1,500 μg
Study: 28931520
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg HIV-MAG DNA vaccine coadministered with pIL-12 at low and medium doses
Study: 28931520
Drug: VSV-Gag vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: VSV-Gag vaccine boost
Study: 28931520
Drug: DNA prime
Normalized name: Toxoplasma gondii DNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: DNA prime with high-dose pIL-12
Study: 28931520
Drug: High-dose pIL-12
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose pIL-12 with DNA prime
Study: 18775100
Drug: Flaxseed-derived lignan
Normalized name: FLAXSEED
DrugBank: Flax seed (DB10708)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flaxseed-derived lignan capsules (360 mg/d)
Study: 17243014
Drug: Delayed treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed treatment control group (n=37)
Study: 15770057
Drug: Ozonated autohemotherapy
Normalized name: ozone
DrugBank: Ozone (DB12510)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ozonated autohemotherapy (ozone concentration of 50 microg/ml)
Study: 7799018
Drug: Paclitaxel administered
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel administered at 135 mg/m2 by 3-hour infusion
Study: 7799018
Drug: Paclitaxel administered
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel administered at 175 mg/m2 by 24-hour infusion
Study: 7799018
Drug: Paclitaxel administered
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel administered at 225 mg/m2 by 3-hour infusion
Study: 7799018
Drug: Duration that
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duration that plasma concentrations of paclitaxel > or = 0.05 mumol/L
Study: 2402844
Drug: Transcutaneous oestradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcutaneous oestradiol treatment
Study: 31086034
Drug: 35 g
Normalized name: SODIUM CHLORIDE 0.135 g in 15 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 35 g enzymatically hydrolyzed collagen protein (EHC)
Study: 31086034
Drug: 35 g
Normalized name: SODIUM CHLORIDE 0.135 g in 15 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 35 g non-enzymatically hydrolyzed collagen protein (NC)
Study: 31086034
Drug: Placebo (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (250 mL water)
Study: 23046782
Drug: Cognitive Behavior
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavior Therapy (CT)
Study: 11714591
Drug: Greater abstinence-specific
Normalized name: greater celandine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Greater abstinence-specific structural support (fewer drug users in the social network)
Study: 11714591
Drug: Decreases in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decreases in negative abstinence-specific functional support (Complaints about Drug Use, Drug Exposure, and Demoralization)
Study: 8993250
Drug: Heparin-coated cardiopulmonary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-coated cardiopulmonary bypass surface (Duraflo II)
Study: 8181028
Drug: Vasodilator therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vasodilator therapy (hydralazine-isosorbide dinitrate)
Study: 2955799
Drug: Orgotein (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orgotein (4 or 8 mg) injected 15 min after each daily radiation treatment
Study: 2955799
Drug: Radiation treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation treatment (63 Gy in 30 fractions)
Study: 24307502
Drug: Parenteral perioperative
Normalized name: ENSURE SURGERY PERIOPERATIVE KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral perioperative antimicrobials (Group I)